Skip to main content
. 2021 Jun 14;13(6):878. doi: 10.3390/pharmaceutics13060878

Figure 6.

Figure 6

Ratio and dose testing in MDA-MB-231 SL and MCF-7 SL. (A,B) Ratio optimization of Cas9 RNP-PF14 (50 ng Cas9/well, formulated in DMEM/PVA-PEG (2.5 w/v%)) given to MDA SL and MCF SL cells. Means of n = 2. (C,D) Dose titration of RNP-PF14 (MR 1:150 RNP to PF14 formulated in DMEM/PVA-PEG (2.5 w/v%)) and RNAiMAX on (C) MDA SL and (D) MCF SL cells, respectively. Linear y-axis against log10 x-axis. n = 3 for PF14-RNP and n = 2 for RNAiMAX.